Methods for treating hair loss disorders

Patent metadata

Field	Value
Publication number	US-10265258-B2
Application number	US-201715668814-A
Country	US
Kind code	B2
Filing date	Aug 4, 2017
Priority date	Nov 2, 2010
Publication date	Apr 23, 2019
Grant date	Apr 23, 2019

Abstract

The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.

First claim

What is claimed:

1. A method of treating alopecia areata in a human in need thereof comprising administering to the human an effective amount of a Janus kinase (JAK) inhibitor having the following structure:

2. The method of claim 1 , wherein the alopecia areata is patchy alopecia areata.

3. The method of claim 1 , wherein the alopecia areata is alopecia totalis.

4. The method of claim 1 , wherein the alopecia areata is alopecia universalis.

5. The method of claim 1 , wherein the effective amount of the JAK inhibitor is administered topically.

6. The method of claim 1 , wherein the effective amount of the JAK inhibitor is administered orally.

7. The method of claim 1 , wherein administering to the human occurs in a route selected from intra-muscular injection, intra-peritoneal injection, an infusion, intravenous, intradermal, subcutaneous, oral, inhalation, transdermal, topical, transmucosal, nasal and rectal.

8. The method of claim 1 , wherein the JAK inhibitor is administered to the human in a pharmaceutical composition selected from a solution, suspension, capsule, tablet, pill, troche, nasal spray, suppository, ointment, salve, gel, and cream.

9. The method of claim 1 , wherein administering to the human occurs twice daily, daily, weekly, twice weekly, monthly, twice monthly, yearly, 1 time per week, 2 times per week, 3 times per week, 4 times per week, 5 times per week, 6 times per week, 7 times per week, 8 times per week, 9 times per week, 10 times per week, 11 times per week, 12 times per week, 13 times per week, or 14 times per week.

10. The method of claim 1 , wherein the JAK inhibitor includes an isotope.

11. The method of claim 1 , wherein the JAK inhibitor includes one or more isotopes of carbon or hydrogen.

12. The method of claim 1 , wherein the method further comprises administering a second JAK inhibitor to said human.

13. The method of claim 1 , wherein the JAK inhibitor is the sole therapeutically active ingredient administered to said human for treating alopecia areata.

14. The method of claim 1 , wherein treating alopecia areata is inducing hair growth.

15. The method of claim 10 , wherein the compound is suitable for nuclear magnetic resonance (NMR).

16. The method of claim 10 , wherein the isotope is a radioisotope.

17. The method of claim 10 , wherein the alopecia areata is patchy alopecia areata.

18. The method of claim 10 , wherein the alopecia areata is alopecia totalis.

19. The method of claim 10 , wherein the alopecia areata is alopecia universalis.

20. The method of claim 10 , wherein the JAK inhibitor is administered topically.

21. The method of claim 10 , wherein JAK inhibitor is administered orally.

22. The method of claim 11 , wherein the JAK inhibitor is suitable for NMR.

23. The method of claim 11 , wherein the isotope is a radioisotope.

24. The method of claim 11 , wherein the alopecia areata is patchy alopecia areata.

25. The method of claim 11 , wherein the alopecia areata is alopecia totalis.

26. The method of claim 11 , wherein the alopecia areata is alopecia universalis.

27. The method of claim 11 , wherein the JAK inhibitor is administered topically.

28. The method of claim 11 , wherein the JAK inhibitor is administered orally.

29. The method of claim 1 , wherein the JAK inhibitor is in a topical pharmaceutical composition at a concentration selected from about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, about 3.0%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, or about 10%.

30. The method of claim 1 , wherein the effective amount of the JAK inhibitor administered to the subject is selected from about 0.0001 μg/kg body weight, about 0.00025 μg/kg body weight, about 0.0005 μg/kg body weight, about 0.00075 μg/kg body weight, about 0.001 μg/kg body weight, about 0.0025 μg/kg body weight, about 0.005 μg/kg body weight, about 0.0075 μg/kg body weight, about 0.01 μg/kg body weight, about 0.025 μg/kg body weight, about 0.05 μg/kg body weight, about 0.075 μg/kg body weight, about 0.1 μg/kg body weight, about 0.25 μg/kg body weight, about 0.5 μg/kg body weight, about 0.75 μg/kg body weight, about 1 μg/kg body weight, about 5 μg/kg body weight, about 10 μg/kg body weight, about 25 μg/kg body weight, about 50 μg/kg body weight, about 75 μg/kg body weight, about 100 μg/kg body weight, about 150 μg/kg body weight, about 200 μg/kg body weight, about 250 μg/kg body weight, about 300 μg/kg body weight, about 350 μg/kg body weight, about 400 μg/kg body weight, about 450 μg/kg body weight, about 500 μg/kg body weight, about 550 μg/kg body weight, about 600 μg/kg body weight, about 650 μg/kg body weight, about 700 μg/kg body weight, about 750 μg/kg body weight, about 800 μg/kg body weight, about 850 μg/kg body weight, about 900 μg/kg body weight, about 950 μg/kg body weight, about 1000 μg/kg body weight, about 2000 μg/kg body weight, about 3000 μg/kg body weight, about 4000 μg/kg body weight, about 5000 μg/kg body weight, about 6000 μg/kg body weight, about 7000 μg/kg body weight, about 8000 μg/kg body weight, about 95000 μg/kg body weight, or about 10,000 μg/kg body weight, about 1 mg/kg body weight, about 1.5 mg/kg body weight, about 2 mg/kg body weight, about 2.5 mg/kg body weight, about 3 mg/kg body weight, about 3.5 mg/kg body weight, about 4 mg/kg body weight, about 4.5 mg/kg body weight, about 5 mg/kg body weight, about 5.5 mg/kg body weight, about 6 mg/kg body weight, about 6.5 mg/kg body weight, about 7 mg/kg body weight, about 7.5 mg/kg body weight, about 8 mg/kg body weight, about 9.5 mg/kg body weight, about 10 mg/kg body weight, about 10.5 mg/kg body weight, about 11.0 mg/kg body weight, about 11.5 mg/kg body weight, about 12 mg/kg body weight, about 12.5 mg/kg body weight, about 13 mg/kg body weight, about 13.5 mg/kg body weight, about 14 mg/kg body weight, about 14.5 mg/kg body weight, about 15 mg/kg body weight, about 15.5 mg/kg body weight, about 16 mg/kg body weight, about 16.5 mg/kg body weight, about 17 mg/kg body weight, about 17.5 mg/kg body weight, about 18 mg/kg body weight, about 19.5 mg/kg body weight, about 20 mg/kg body weight, about 21.5 mg/kg body weight, about 22 mg/kg body weight, about 22.5 mg/kg body weight, about 23 mg/kg body weight, about 23.5 mg/kg body weight, about 24 mg/kg body weight, about 24.5 mg/kg body weight, about 25 mg/kg body weight, about 25.5 mg/kg body weight, about 26 mg/kg body weight, about 26.5 mg/kg body weight, about 27 mg/kg body weight, about 27.5 mg/kg body weight, about 28 mg/kg body weight, about 29.5 mg/kg body weight, or about 30 mg/kg body weight.

31. The method of claim 1 , wherein administering to the subject occurs for at least 1 week.

Assignees

• Univ Columbia

Inventors

• Christiano Angela M
• Clynes Raphael

Classifications

• A61K31/7052

  having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides · CPC title

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K31/277

  having a ring, e.g. verapamil · CPC title

• A61K31/553

  having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine · CPC title